Gene therapy SKY-GJB2 for children with GJB2-related hearing loss
Tests the gene therapy SKY-GJB2 in young children with GJB2-related hearing loss.
Key facts
- Who runs it
- Skylark Bio Inc.
- Where
- Allentown, Bethesda, Boston, and Oklahoma City, United StatesSee the 4 sites
- Trial code
- Registry title
- Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 10 people, planned
- Started
- 28 May 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- SKY-GJB2
- Record updated
- 27 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young children with hearing loss in both ears caused by changes in the GJB2 gene. They get a one-time gene therapy, SKY-GJB2, into one inner ear.
- Age
- 9 months to 7 years at the time of the gene therapy.
- Sex
- Boys and girls can join.
- Disease stage
- Hearing loss in both ears from the inner ear or hearing nerve (sensorineural), measured by an ABR hearing test. In the treated ear, hearing loss must be ≥85 dB HL at one or more frequencies (500-4000 Hz).
- Earlier treatment
- Children with cochlear implants in both ears cannot join.
- Biomarker or test result
- At least two (biallelic) disease-causing or likely disease-causing changes in the GJB2 gene.
Main reasons for not taking part
- Hearing loss not caused by GJB2 changes, including other genetic or syndrome-related hearing loss
- Autosomal dominant nonsyndromic hearing loss due to a GJB2 change
- No response on the ABR hearing test
- Cochlear implants in both ears
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female aged 9 months to 7 years at the time of gene therapy administration
- Subjects must have at least two (biallelic) pathogenic or likely pathogenic variants in the GJB2 gene
- Bilateral sensorineural hearing loss as assessed by ABR. Hearing loss at ≥85 dB HL for at least one of the frequencies (500-4000 Hz) in the study treatment ear
- Subject's parent(s)/guardian(s) provide informed consent before the initiation of study-related procedures
- Subject is able and willing to comply (or provide assent if old enough) will all study requirements
Who cannot take part
- Bilateral Cochlear Implants
- Subject has non-GJB2 mediated hearing loss including genetic, syndromic, or non-syndromic hearing loss that is not associated with GJB2 mutations
- Subject has autosomal dominant nonsyndromic hearing loss due to GJB2 mutation
- No response on ABR testing
Where in United States
- Lehigh Valley Hospital-Cedar CrestAllentown, United StatesContact: Ravi N. Samy, MD, FACSTaking people
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Maame Akumatey (Study Coordinator)Taking people
- Massachusetts Eye and Ear Infirmary(MEEI)Boston, United StatesContact: Michael Cheung, MSc, CCRP, Clinical Research Project ManagerTaking people
- Hearts for Hearing-Oklahoma CityOklahoma City, United StatesContact: René Gifford, PhDTaking people
About the trial
What the trial wants to find out
Skylark Bio is conducting a study of an investigational new drug called SKY-GJB2 and its delivery device, the SKY-CAT. SKY-GJB2 is a gene therapy that is being developed to treat children who have hearing loss due to changes in the GJB2 gene (also referred to as Connexin 26). The SKY-CAT is a device that delivers the gene therapy.
Read full original descriptionShow less
The purpose of this study is to:
Learn about the safety and tolerability (does not cause ongoing discomfort) of SKY-GJB2 Evaluate the efficacy of SKY-GJB2 (how well is works)
The 2 groups in the trial
- OlderTreatment being tested
Four subjects aged 2 to 7 years old (inclusive) to receive an intracochlear infusion of SKY-GJB2 in the study ear using a sterile, one-time use investigational medical device.
Treatment: SKY-GJB2
- YoungerTreatment being tested
Six subjects aged 9 months to less than 2 years old to receive an intracochlear infusion of SKY-GJB2 in the study ear using a sterile, one-time use investigational medical device.
Treatment: SKY-GJB2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1/2, Open-label, Single Dose Study of SKY-GJB2 Given as a Single Unilateral Intracochlear Administration in Pediatric Subjects With GJB2-mediated Hearing Loss
- Plain-language title
- Gene therapy SKY-GJB2 for children with GJB2-related hearing lossGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 August 2026